Blood：治疗慢性疾病和糖尿病伤口的新药物

近日，瑞典Umeå大学开发出了一个独特的新药物，该药物可以启动和加快糖尿病和其他慢性疾病的伤口愈合。这一药物是经过几年的实验研究而获得成功的，目前正准备进行临床试验。研究人员证实纤维蛋白溶酶原是一个触发炎症反应的启动和加速伤口愈合的关键调节因子，相关研究论文发表在Blood杂志上。

纤溶酶是一个众所周知的血浆蛋白，主要在肝脏中产生，在所有体液中都存在。Umeå研究人员现在重新评估纤溶酶的作用，揭示了与伤口内部以及周围部位纤溶酶原浓度的急剧增加，这一信号是愈合所需的炎症反应启动的关键。糖尿病伤口的纤维蛋白溶酶原水平不会以同样的方式增加，这似乎解释了为什么这些伤口不愈合的原因。在糖尿病小鼠和大鼠研究中，研究人员在伤口周围注射纤溶酶启动愈合过程，结果发现伤口完全愈合。

一个能产生纤维蛋白溶酶原的细胞株也已被开发，我们的目标是尽快获得资金来开始临床试验。研究人员认为纤维蛋白溶酶原是一种内源性蛋白，产生副作用的可能性不大。起初Umeå研究人员最初集中在糖尿病伤口愈合上，但纤维蛋白溶酶原在有其他类型的伤口症状的疾病中也有功效。

doi: 10.1182/blood-2012-01-407825
PMC:
PMID:

Plasminogen is a key pro-inflammatory regulator that accelerates the healing of acute and diabetic wounds

Y. Shen, Y. Guo, P. Mikus, R. Sulniute, M. Wilczynska, T. Ny, J. Li.

Despite decades of research on wound healing, effective biologic agents for the treatment of chronic wounds, especially diabetic wounds, are still lacking. In this study, we report that the inert plasma protein plasminogen (plg) acts as a key regulatory molecule that potentiates wound healing in mice. Early in the healing process, plg bound to inflammatory cells is transported to the wound area, where the level of plg is locally increased. This leads to induction of cytokines and intracellular signaling events and to a potentiation of the early inflammatory response. Systemic administration of additional plg not only accelerates the healing of acute burn wounds in wild-type mice but also improves the healing of chronic diabetic wounds in a mouse model of diabetes. Our results suggest that administration of plg may be a novel therapeutic strategy to treat many different types of wounds, especially those that are chronic, such as diabetic wounds.